Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, Herpin B, Perry C, Hallahan CW, Davey RT, Metcalf JA, Connors M, Fauci AS. Dybul M, et al. Among authors: metcalf ja. J Infect Dis. 2002 Jan 1;185(1):61-8. doi: 10.1086/338123. Epub 2001 Dec 14. J Infect Dis. 2002. PMID: 11756982 Clinical Trial.
Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover.
Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, Falloon J, Polis MA, Lane HC, Sereti I. Anthony KB, et al. Among authors: metcalf ja. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):125-33. doi: 10.1097/00126334-200306010-00002. J Acquir Immune Defic Syndr. 2003. PMID: 12794543
Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.
Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS. Dybul M, et al. Among authors: metcalf ja. J Infect Dis. 2003 Aug 1;188(3):388-96. doi: 10.1086/376535. Epub 2003 Jul 10. J Infect Dis. 2003. PMID: 12870120 Clinical Trial.
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. Tavel JA, et al. Among authors: metcalf ja. J Infect Dis. 2003 Aug 15;188(4):531-6. doi: 10.1086/377285. Epub 2003 Jul 31. J Infect Dis. 2003. PMID: 12898439 Clinical Trial.
In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.
Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, Powers A, Davey RT, Kovacs JA, Shevach EM, Lane HC. Sereti I, et al. Among authors: metcalf ja. J Clin Invest. 2005 Jul;115(7):1839-47. doi: 10.1172/JCI24307. Epub 2005 Jun 2. J Clin Invest. 2005. PMID: 15937547 Free PMC article. Clinical Trial.
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.
Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Issaq HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC. Kovacs JA, et al. Among authors: metcalf ja. J Clin Invest. 2005 Aug;115(8):2139-48. doi: 10.1172/JCI23196. Epub 2005 Jul 14. J Clin Invest. 2005. PMID: 16025158 Free PMC article.
191 results